The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2025 | Peters Malte | Chief Executive Officer, Director | Sell(S) | 25K | $0.82 | $21K |
| Jul 22, 2025 | Coelho Mary Theresa | EVP and CFO, Director | Sell(S) | 14K | $0.92 | $13K |
| Jul 22, 2025 | Peters Malte | Chief Executive Officer, Director | Sell(S) | 29K | $0.92 | $27K |
| Jul 22, 2024 | Cassidy Sean A | Director | Grant(A) | 10K | — | $0 |
| Jul 22, 2024 | Peters Malte | Chief Executive Officer, Director | Grant(A) | 109K | — | $0 |
| Jul 22, 2024 | Coelho Mary Theresa | EVP and CFO, Director | Grant(A) | 70K | — | $0 |
| Jun 17, 2024 | Reilly Timothy P. | Director | Grant(A) | 49K | — | $0 |
| Jun 17, 2024 | O'Neill Julie | Director | Grant(A) | 49K | — | $0 |
| Jun 17, 2024 | Coelho Mary Theresa | Director | Grant(A) | 49K | — | $0 |
| Jun 17, 2024 | Kaufman David Ross | Director | Grant(A) | 49K | — | $0 |
| Jun 17, 2024 | Peters Malte | Director | Grant(A) | 49K | — | $0 |
| Jun 17, 2024 | van de Winkel Jan | Director | Grant(A) | 98K | — | $0 |
| Apr 15, 2024 | Necina Roman | Chief Operations Officer | Grant(A) | 367K | — | $0 |
| Apr 15, 2024 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 971K | — | $0 |
| Apr 15, 2024 | Orlinger Klaus | Chief Scientific Officer | Grant(A) | 367K | — | $0 |
| Apr 15, 2024 | Kandera Reinhard | Chief Financial Officer, Director | Grant(A) | 406K | — | $0 |
| Apr 15, 2024 | Winderlich Mark | Chief Development Officer | Grant(A) | 250K | — | $0 |
| Apr 15, 2024 | Winderlich Mark | Chief Development Officer | Grant(A) | 50K | — | $0 |
| Aug 21, 2023 | Kandera Reinhard | Chief Financial Officer, Director | Buy(P) | 7K | $0.73 | $5K |
| Aug 16, 2023 | Kandera Reinhard | Chief Financial Officer, Director | Buy(P) | 8K | $0.71 | $6K |
| Jul 11, 2023 | Aldag Jorn | Chief Executive Officer, Director | Buy(P) | 5K | $0.83 | $4K |
| Jul 7, 2023 | Aldag Jorn | Chief Executive Officer, Director | Buy(P) | 5K | $0.81 | $4K |
| Jul 5, 2023 | Aldag Jorn | Chief Executive Officer, Director | Buy(P) | 5K | $0.89 | $4K |
| Jul 3, 2023 | Aldag Jorn | Chief Executive Officer, Director | Buy(P) | 5K | $0.89 | $4K |
| Jun 30, 2023 | Kandera Reinhard | Chief Financial Officer, Director | Buy(P) | 12K | $0.88 | $11K |
| Jun 9, 2023 | Coelho Mary Theresa | Director | Grant(A) | 52K | — | $0 |
| Jun 9, 2023 | Kaufman David Ross | Director | Grant(A) | 26K | — | $0 |
| Jun 9, 2023 | van de Winkel Jan | Director | Grant(A) | 52K | — | $0 |
| Jun 9, 2023 | O'Neill Julie | Director | Grant(A) | 26K | — | $0 |
| Jun 9, 2023 | Reilly Timothy P. | Director | Grant(A) | 26K | — | $0 |
| Jun 9, 2023 | Peters Malte | Director | Grant(A) | 52K | — | $0 |
| Apr 14, 2023 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 514K | — | $0 |
| Apr 14, 2023 | Kandera Reinhard | Chief Financial Officer, Director | Grant(A) | 215K | — | $0 |
| Apr 14, 2023 | Baker Christine D. | Chief Operating Officer | Grant(A) | 276K | — | $0 |
| Apr 14, 2023 | Schlienger Katia | Chief Medical Officer | Grant(A) | 184K | — | $0 |
| Apr 14, 2023 | Necina Roman | Chief Development Officer | Grant(A) | 112K | — | $0 |
| Apr 14, 2023 | Orlinger Klaus | Chief Scientific Officer | Grant(A) | 194K | — | $0 |
| Jun 30, 2022 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 275K | — | $0 |
| Jun 30, 2022 | Baker Christine D. | Chief Operating Officer | Grant(A) | 100K | — | $0 |
| Jun 30, 2022 | Kandera Reinhard | Chief Financial Officer, Director | Grant(A) | 93K | — | $0 |
| Jun 30, 2022 | Kaufman David Ross | Director | Grant(A) | 20K | — | $0 |
| Jun 30, 2022 | Kelly Michael Aaron | Director | Grant(A) | 20K | — | $0 |
| Jun 30, 2022 | Matushansky Igor | Chief Medical Officer | Grant(A) | 93K | — | $0 |
| Jun 30, 2022 | Necina Roman | Chief Technology Officer | Grant(A) | 48K | — | $0 |
| Jun 30, 2022 | O'Neill Julie | Director | Grant(A) | 20K | — | $0 |
| Jun 30, 2022 | Orlinger Klaus | Chief Scientific Officer | Grant(A) | 48K | — | $0 |
| Jun 30, 2022 | Reilly Timothy P. | Director | Grant(A) | 40K | — | $0 |
| Jun 30, 2022 | van de Winkel Jan | Director | Grant(A) | 40K | — | $0 |
| Apr 19, 2022 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 275K | — | $0 |
| Apr 19, 2022 | Baker Christine D. | Chief Business Officer | Grant(A) | 100K | — | $0 |
| Apr 19, 2022 | Kandera Reinhard | Chief Financial Officer, Director | Grant(A) | 93K | — | $0 |
| Apr 19, 2022 | Matushansky Igor | Chief Medical Officer | Grant(A) | 93K | — | $0 |
| Apr 19, 2022 | Necina Roman | Chief Technology Officer | Grant(A) | 48K | — | $0 |
| Apr 19, 2022 | Orlinger Klaus | Chief Scientific Officer | Grant(A) | 48K | — | $0 |
| Feb 1, 2022 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 48K | $3.00 | $143K |
| Feb 1, 2022 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 40K | $3.00 | $120K |
| Feb 1, 2022 | Kandera Reinhard | Chief Financial Officer, Director | Grant(A) | 14K | $3.00 | $42K |
| Feb 1, 2022 | Kandera Reinhard | Chief Financial Officer, Director | Grant(A) | 23K | $3.00 | $70K |
| Feb 1, 2022 | Matushansky Igor | Chief Medical Officer | Grant(A) | 15K | $3.00 | $45K |
| Feb 1, 2022 | Matushansky Igor | Chief Medical Officer | Grant(A) | 25K | $3.00 | $75K |
| Feb 1, 2022 | Necina Roman | Chief Technology Officer | Grant(A) | 13K | $3.00 | $39K |
| Feb 1, 2022 | Necina Roman | Chief Technology Officer | Grant(A) | 21K | $3.00 | $64K |
| Feb 1, 2022 | Baker Christine D. | Chief Business Officer | Grant(A) | 14K | $3.00 | $41K |
| Feb 1, 2022 | Baker Christine D. | Chief Business Officer | Grant(A) | 23K | $3.00 | $68K |
| Feb 1, 2022 | Orlinger Klaus | Executive VP, Research | Grant(A) | 9K | $3.00 | $28K |
| Feb 1, 2022 | Orlinger Klaus | Executive VP, Research | Grant(A) | 13K | $3.00 | $38K |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Option exercise(M) | 8K | $0.10 | $808 |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Option exercise(M) | 3K | $0.10 | $341 |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Sell(S) | 7K | $2.49 | $19K |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Option exercise(M) | 11K | $0.10 | $1K |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Sell(S) | 5K | $2.49 | $13K |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Sell(S) | 2K | $2.49 | $5K |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Option exercise(M) | 3K | — | $0 |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Option exercise(M) | 11K | — | $0 |
| Dec 21, 2021 | Matushansky Igor | Chief Medical Officer | Option exercise(M) | 8K | — | $0 |
| Jun 1, 2021 | Kaufman David Ross | Director | Grant(A) | 10K | — | $0 |
| Jun 1, 2021 | Kelly Michael Aaron | Director | Grant(A) | 10K | — | $0 |
| Jun 1, 2021 | Lengauer Christoph | Director | Grant(A) | 10K | — | $0 |
| Jun 1, 2021 | O'Neill Julie | Director | Grant(A) | 10K | — | $0 |
| Jun 1, 2021 | Seghezzi Graziano | Director | Grant(A) | 10K | — | $0 |
| Jun 1, 2021 | Soria Jean-Charles | Director | Grant(A) | 10K | — | $0 |
| Jun 1, 2021 | van de Winkel Jan | Director | Grant(A) | 19K | — | $0 |
| Apr 21, 2021 | Sofinnova Partners SAS | 10% Owner | Sell(S) | 329K | $11.60 | $3.8M |
| Apr 19, 2021 | Aldag Jorn | Chief Executive Officer, Director | Grant(A) | 208K | — | $0 |
| Apr 19, 2021 | Kandera Reinhard | Chief Financial Officer | Grant(A) | 69K | — | $0 |
| Apr 19, 2021 | Matushansky Igor | Chief Medical Officer | Grant(A) | 95K | — | $0 |
| Apr 19, 2021 | Baker Christine D. | Chief Business Officer | Grant(A) | 50K | — | $0 |
| Apr 19, 2021 | Orlinger Klaus | Sr. VP, Research | Grant(A) | 26K | — | $0 |
| Apr 19, 2021 | Necina Roman | Chief Technology Officer | Grant(A) | 37K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).